Pfizer Strengthens Focus on Business in China
  Al Gabor takes regional leadership role as Ahmet Esen is appointed new China General Manager and Chairman
Share :  
  • Beijing    March 28, 2006

  • In a move reflecting the increasing importance of China within the Asia Pacific, Pfizer today announced the promotion of Mr. Allan Gabor, Pfizer China's General Manager and Chairman, to the regional leadership position of Vice President of Pfizer Global Pharmaceutical (PGP) Asia Region. In his new position, Mr. Gabor will have direct responsibility for China, Hong Kong, Indonesia, India, Pakistan, the Philippines and Thailand. Mr. Gabor will also lead key regional strategic initiatives, spanning across the Asia Pacific.

    While serving as General Manager and CEO of Pfizer China, Mr Gabor successfully directed the launch of many of Pfizer's innovative medicines into China. Under Gabor's leadership, Pfizer opened the China Regional Investment Center and a state of the art research and development center in Shanghai. Additionally, Mr. Gabor led Pfizer China's philanthropic efforts that placed the company third and sixth on Forbes 2004 and 2005 China Charity List respectively. The promotion of Mr. Gabor to Vice President of PGP Asia Region is significant as it underscores the importance of China to the entire Asia Pacific strategy of Pfizer.

    Pfizer is also pleased to announce longtime company veteran, Mr. Ahmet Esen, as successor to Mr. Gabor. Mr. Esen's 27 years of experience has spanned many of Pfizer's business divisions including Technical, Human Resources, Finance and Sales. In 1993, Ahmet was appointed General Manager of Pfizer Pakistan, and in 1995 he assumed the position of Executive HR Director for Northern Asia, Australia and Canada. A year later, he was transferred from this post in New York to South Africa, where he served as Regional Director South-Central Africa. In 1999, he returned to Turkey as its General Manager.

    "Mr. Esen brings a gifted, and unique, set of skills to our China operation," commented Mr. Gabor. "I believe he will perfectly compliment the successes of Pfizer China in his new position and improve our ability to provide for the needs of the Chinese people."

    As the new China General Manager and Chairman, Mr. Esen will lead Pfizer's efforts to continue the growth and progress that has been made since Pfizer's entrance into China. "Pfizer globally is very proud of our accomplishments in China," said Mr. Esen. "Pfizer entered the China market in the 1980s, and by following a long-term vision for development, it has seen great success, including working to ensure that China's people live happier, healthier lives. I will do my very best to continue and build on this legacy."

    Pfizer is a global research-based company, discovering, developing, manufacturing and marketing leading prescription medicines for humans and animals and many of the world's best-known consumer brands. To date, Pfizer has invested more than US$500 million in China. With an unequalled product portfolio, Pfizer China remains a strong leader in the therapeutic areas of cardiovascular disease, endocrinology, neuroscience, arthritis and other inflammatory diseases, infectious disease, urology and oncology.

Text SizeAAA